Publications
314 results found
Dreher M, Price D, Gardev A, et al., 2020, Late Breaking Abstract - Switching from a disposable to a re-usable inhaler: patient satisfaction and preference, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Biddiscombe M, Matthews J, Wright M, et al., 2020, No evidence electric charge increases inhaled ultrafine particle deposition in human lungs, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Kocks J, Andringa H, Van Heijst E, et al., 2020, The sensitivity and specificity of specific IgE in diagnosing asthma, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Satia I, Nagashima A, Usmani OS, 2020, Exploring the role of nerves in asthma; insights from the study of cough, BIOCHEMICAL PHARMACOLOGY, Vol: 179, ISSN: 0006-2952
- Author Web Link
- Cite
- Citations: 11
Verbanck S, Biddiscombe MF, Usmani OS, 2020, Inhaled aerosol dose distribution between proximal bronchi and lung periphery, European Journal of Pharmaceutics and Biopharmaceutics, Vol: 152, Pages: 18-22, ISSN: 0939-6411
Modern inhaled drug discovery programs assess dose delivery to proximal and distal airways using rudimentary imaging indices, where relative deposition is estimated by generically defined 'central' and 'peripheral' lung regions. Utilizing recent data linking the proximal airway topology to a characteristic pattern of aerosol lung deposition, we provide a direct measure of dose distribution between the proximal bronchi and the distal lung. We analyzed scintigraphic lung images of twelve asthma patients following inhalation of 1.5-, 3- and 6-µm monodisperse drug particles at breathing flows of 30- and 60-L/min. We explicitly used the central hot-spots associated with each patient's specific bronchial topology to obtain a direct measure of aerosol deposition in the proximal bronchi, rather than applying standard templates of lung boundaries. Maximum deposition in the central bronchi (as % of lung deposition) was 52±10(SD)% (6µm;60L/min). Minimum central deposition was 17±2(SD)% (1.5µm;30L/min) where the 83% aerosol 'escaping' deposition in the central bronchi reached 75±17(SD)% of the lung area that could be reached by Krypton gas. For all particle sizes, hot-spots appeared in the same patient-specific central airway location, with greatest intensity at 60L/min. For a range of respirable aerosol sizes and breathing flows, we have quantified deposited dose in the proximal bronchi and their distal lung reach, constituting a platform to support therapeutic inhaled aerosol drug development.
Usmani OS, 2020, Calling time on spirometry: unlocking the silent zone in acute rejection after lung transplantation, American Journal of Respiratory and Critical Care Medicine, Vol: 201, Pages: 1468-1470, ISSN: 1073-449X
Khusial RJ, Honkoop PJ, Usmani O, et al., 2020, Effectiveness of myAirCoach: A mHealth Self-Management System in Asthma, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, Vol: 8, Pages: 1972-+, ISSN: 2213-2198
- Author Web Link
- Cite
- Citations: 23
Usmani OS, Matthews JC, Wright MD, et al., 2020, No evidence electric charge increases inhaled ultrafine particle deposition in human lungs, American Journal of Respiratory and Critical Care Medicine, Vol: 201, Pages: 1301-1303, ISSN: 1073-449X
Cazzola M, Cavalli F, Usmani OS, et al., 2020, Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease, EXPERT OPINION ON DRUG DELIVERY, Vol: 17, Pages: 635-646, ISSN: 1742-5247
- Author Web Link
- Cite
- Citations: 31
Bonini M, Usmani OS, 2020, Drugs for airway disease, Medicine (United Kingdom), Vol: 48, Pages: 314-322, ISSN: 1357-3039
Asthma is a heterogeneous disease characterized by chronic airway inflammation and variable expiratory airflow limitation. It affects 5–15% of people worldwide and has shown an increasing prevalence over the last decade. The treatment of asthma is well established in current guidelines, with the aim of achieving optimal disease control and preventing acute exacerbations using a stepwise medication approach. Drugs are commonly divided into ‘relievers’, which quickly reverse airway obstruction, and ‘controllers’, which target the underlying inflammation providing long-term control. β2-adrenoceptor agonists are the most effective therapy for preventing and treating bronchial obstruction, while inhaled corticosteroids are recommended as first-line chronic therapy for persistent asthma. Drugs such as muscarinic antagonists, anti-leukotrienes and macrolides also play a role in disease management. New personalized therapies, such as biological agents or small molecules, have become available or are under development for treatment of severe asthma, together presenting opportunities with developments in biomarkers for interventions of precision medicine.
Moitra S, Moitra S, Ghosh AK, et al., 2020, Reference values of impulse oscillometry (IOS) for healthy Indian adults, International Journal of Tuberculosis and Lung Disease, Vol: 24, Pages: 536-539, ISSN: 1027-3719
Keeley D, Scullion JE, Usmani OS, 2020, Minimising the environmental impact of inhaled therapies, EUROPEAN RESPIRATORY JOURNAL, Vol: 55, ISSN: 0903-1936
Lavorini F, Barreto C, van Boven JFM, et al., 2020, Spacers and Valved Holding Chambers?The Risk of Switching to Different Chambers, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, Vol: 8, Pages: 1569-1573, ISSN: 2213-2198
- Author Web Link
- Cite
- Citations: 9
Keeley D, Scullion JE, Usmani OS, 2020, Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers., Eur Respir J, Vol: 55
Bloom C, Douglas I, Usmani OS, et al., 2020, Inhaled corticosteroid treatment regimens and health outcomes in a UK COPD population study [Corrigendum], The International Journal of Chronic Obstructive Pulmonary Disease, Vol: 15, Pages: 869-869, ISSN: 1176-9106
Bloom CI, Douglas I, Usmani OS, et al., 2020, Inhaled corticosteroid treatment regimens and health outcomes in a UK COPD population study, The International Journal of Chronic Obstructive Pulmonary Disease, Vol: 15, Pages: 701-710, ISSN: 1176-9106
Background: Inhaled corticosteroids (ICS) are a prevailing treatment option for COPD patients but recent guidelines have relegated their use predominantly to patients with frequent exacerbations. Yet large numbers of patients worldwide are currently treated with ICS-containing regimens. We wished to determine in routine clinical practice how common ICS withdrawal is and the differences in health outcomes between patients managed on ICS-containing and non-ICS containing regimens.Patients and Methods: COPD patients were identified from the UK primary care electronic healthcare records, between 2014 and 2018. Patients were grouped into three treatment regimens: long-acting beta-agonist (LABA) and inhaled corticosteroids (ICS), LABA and long-acting muscarinic antagonist (LAMA), and triple therapy (LABA, LAMA and ICS). Annual incidence of ICS withdrawal was measured. Multivariable logistic regression was used to identify patient factors associated with withdrawal. Multivariable Poisson regression was used to assess the association of exacerbations and hospitalised pneumonia between the ICS-containing regimens (LABA-ICS and triple therapy) and patients prescribed LABA-LAMA.Results: Of 117,046 patients, around three-quarters were prescribed ICS-containing inhalers but ICS withdrawal occurred annually in only approximately 2– 3% of patients. Exacerbations in the past year, but not a past history of pneumonia, were associated with ICS withdrawal. A total of 31,034 patients using three treatment regimens (LABA-ICS, LABA-LAMA or triple therapy) were assessed for their relative risk of exacerbations and pneumonia; the exacerbation risk was slightly lower in LABA-ICS users but the same in triple therapy users, as compared to LABA-LAMA users (LABA-ICS adjusted IRR=0.82 (95% CI 0.73– 0.93), triple adjusted IRR=0.99 (95% CI 0.88– 1.11)). There was no difference in the pneumonia risk (LABA-ICS adjusted IRR=0.96 (95% CI 0.71– 1.31), triple adjusted IRR=1.16 (
Alving K, Diamant Z, Lucas S, et al., 2020, Point-of-care biomarkers in asthma management: Time to move forward, ALLERGY, Vol: 75, Pages: 995-997, ISSN: 0105-4538
Usmani OS, Mignot B, Belmans D, et al., 2020, Lung deposition of extrafine vs. non-extrafine tiple therapies in patients with COPD using Functional Respiratory Imaging (FRI), Publisher: GEORG THIEME VERLAG KG, Pages: S88-S88, ISSN: 0934-8387
Lahousse L, Bahmer T, Cuevas-Ocaña S, et al., 2020, ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly, ERJ Open Research, Vol: 6, ISSN: 2312-0541
The European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain, was a platform for scientific discussion of the highest quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses some of the high-quality research studies presented at that Congress, with a focus on airway diseases, including asthma, COPD, small airways, bronchiectasis and cough, presented through the Airway Diseases, Asthma and COPD Assembly (Assembly 5) of the ERS. The authors establish the key take-home messages of these studies, compare their findings and place them into context of current understanding.
Keeley D, Scullion JE, Usmani OS, 2020, Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers, EUROPEAN RESPIRATORY JOURNAL, Vol: 55, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 13
Spanevello A, Usmani O, Osmonov BR, et al., 2020, Masterclass in airways disease: course report., Breathe (Sheff), Vol: 15, Pages: e132-e134, ISSN: 1810-6838
Roche N, Anzueto A, Anticevich SB, et al., 2020, Connected real-life research, a pillar of P4 medicine, EUROPEAN RESPIRATORY JOURNAL, Vol: 55, ISSN: 0903-1936
Usmani OS, 2020, Feasibility of Aerosolized Alpha-1-Antitrypsin as a Therapeutic Option, CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, Vol: 7, Pages: 272-279, ISSN: 2372-952X
- Author Web Link
- Cite
- Citations: 6
Dolovich MB, Kuttler A, Dimke TJ, et al., 2019, Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler, International Journal of Pharmaceutics: X, Vol: 1, Pages: 1-9, ISSN: 2590-1567
A biophysical lung model was designed to predict inhaled drug deposition in patients with obstructive airway disease, and quantitatively investigate sources of deposition variability. Different mouth-throat anatomies at varying simulated inhalation flows were used to calculate the lung dose of indacaterol/glycopyrronium [IND/GLY] 110/50 µg (QVA149) from the dry-powder inhaler Breezhaler®. Sources of variability in lung dose were studied using computational fluid dynamics, supported by aerosol particle sizing measurements, particle image velocimetry and computed tomography. Anatomical differences in mouth-throat geometries were identified as a major source of inter-subject variability in lung deposition. Lung dose was similar across inhalation flows of 30–120 L/min with a slight drop in calculated delivery at high inspiratory flows. Delivery was relatively unaffected by inhaler inclination angle. The delivered lung dose of the fixed-dose combination IND/GLY matched well with corresponding monotherapy doses. This biophysical model indicates low extra-thoracic drug loss and consistent lung delivery of IND/GLY, independent of inhalation flows. This is an important finding for patients across various ages and lung disease severities. The model provides a quantitative, mechanistic simulation of inhaled therapies that could provide a test system for estimating drug delivery to the lung and complement traditional clinical studies.
Seys SF, Quirce S, Agache I, et al., 2019, Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018, ALLERGY, Vol: 74, Pages: 2244-2248, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 13
Mehta B, Edwards S, Hopkinson N, et al., 2019, Time is Essential for Competant Inhaler Technique Training, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Topole E, Usmani O, Mignot B, et al., 2019, Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI), International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 2
Lewis H, Dickinson E, Usmani OS, 2019, Opinions on the environmental impact of inhaler devices in UK respiratory care, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Khusial R, Honkoop PJ, Usmani O, et al., 2019, myAirCoach: mHealth assisted self-management in patients with uncontrolled asthma, a randomized control trial, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 3
Roche N, Anzueto A, Anticevich SB, et al., 2019, The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group, European Respiratory Journal, Vol: 54, Pages: 1-6, ISSN: 0903-1936
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.